BSE filing, NSE: NECLIFE. Summary written from the filing by ALFA Finder's alert engine.
Nectar Lifesciences Ltd: key numbers
- Share price
- ₹10.34
- Market cap
- ₹231.9 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-292.9 Cr
- P/E (TTM)
- -0.9×Sector 46.1×
- Promoter holding
- 51.84%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nectar Lifesciences Ltd
All →Nectar Lifesciences Other Announcement
Nectar Lifesciences Ltd has filed its quarterly shareholding pattern as per SEBI regulations. The document details the promoter group and public shareholding for the quarter.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences Limited submitted the minutes of its 31st Annual General Meeting held on September 18, 2026. Shareholders approved financial statements and the re-appointment of directors.
Nectar Lifesciences Legal & Regulatory
Nectar Lifesciences provided an update on a material tax litigation where the High Court remanded the matter to the Appellate Authority for fresh consideration.
Nectar Lifesciences Management Change
Nectar Lifesciences Limited has announced the appointment of Dr. Gunmala Suri as a Director. Additionally, three other directors have been re-appointed to the Board.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences filed proceedings of its 31st AGM held September 18, 2026. Resolutions covered adoption of FY26 financials and director re-appointments.
Nectar Lifesciences Annual Report
Nectar Lifesciences Ltd. has released its Annual Report for FY 2025-26. The 31st Annual General Meeting is scheduled for September 18, 2026, via video conferencing.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr